OSI Pharma Acquired by Astellas for $4 Billion
May 16, 2010 at 21:50 PM EDT
Astellas Pharma Inc., Japan’s No.2 drugmaker, said on Sunday that it had agreed to buy U.S. biotech OSI Pharma (OSIP) for $4 billion in cash. Under the terms of the merger agreement, Astellas will add OSI’s blockbuster cancer drug Tarceva to its line-up and will increase its offer price to $57.50 per share, [...]
